alexa
Reach Us +44-1477412632
Arginine Vasopressin: What Else Does It Do? | 35472
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Arginine vasopressin: What else does it do?

4th International Conference on Nephrology & Therapeutics

Michael F Michelis

Lenox Hill Hospital, USA

ScientificTracks Abstracts: J Nephrol Ther

DOI: 10.4172/2161-0959.C1.018

Abstract
The pressor and antidiuretic actions of arginine vasopressin (AVP) have been well documented. It is also important to focus on less widely appreciated actions of AVP. In addition to effects on hemostasis, pain, aging, social behavior and cognition, AVP has important relationships to bone metabolism and a variety of metabolic systems which involve changes that have significant effects on nephrologic outcomes. These include involvement with the hypothalamic-pituitary-axis, inflammatory responses, cell proliferation and reaction to urinary infection, as well as components of the metabolic syndrome such as diabetes mellitus, lipid metabolism and hypertension. Finally, possible direct effects of AVP on the progression of chronic kidney disease will be considered.
Biography

Michael F Michelis is Director of Nephrology at Lenox Hill Hospital in New York and Clinical Professor of Medicine at New York University School of Medicine. He received his training in renal disease at the University of Pittsburgh and was a member of the faculty there before moving to New York. He is a Fellow of the American College of Physicians, a Specialist in Clinical Hypertension and a Fellow of the American Society of Nephrology. He has been a principal investigator on many clinical trials and has authored numerous publications. He directed clinical studies which characterized an unrecognized genetic kidney disease now referred to as Michelis-Castrillo Syndrome.

Email: [email protected]

Top